Screener
Moderna MRNA Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Moderna in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Moderna’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001682852-26-000060
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Investments, non-current | 2,251 | 2,336 |
| Property, plant and equipment, net | 2,086 | 2,134 |
| Right-of-use assets, operating leases | 706 | 719 |
| Other non-current assets | 675 | 605 |
| Total assets | $11,488 | $12,338 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $161 | $317 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Moderna's deferred tax assets and other non-current assets?
- Moderna (MRNA) reported deferred tax assets and other non-current assets of $675M in Q1 2026.
- How has Moderna's deferred tax assets and other non-current assets changed year-over-year?
- Moderna's deferred tax assets and other non-current assets increased by 21.4% year-over-year, from $556M to $675M.
- What is the long-term trend for Moderna's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Moderna's deferred tax assets and other non-current assets has grown at a 213.4% compound annual growth rate (CAGR), from $2M to $605M.
Ask your AI about Moderna's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude